文献速递消化道肿瘤放疗放疗物理与技术

质子束同步放化疗治疗不可切除局部晚期胰腺癌

Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer.
PubMed 文献 · Radiother Oncol · 2019-04-06

回顾性分析42例不可切除局部晚期胰腺癌患者接受质子束同步放化疗的结果,其中12例接受50 GyE/25次常规剂量方案,30例接受54.0-67.5 GyE/25-33次高剂量方案,同步使用吉西他滨或S-1。1年/2年总生存率为77.8%/50.8%,中位生存时间25.6个月;1年/2年局部控制率为83.3%/78.9%。总照射剂量是总生存和局部控制的唯一显著因素(p=0.015和0.023)。

要点

  • 质子束同步放化疗后1年/2年总生存率77.8%/50.8%,中位生存时间25.6个月。
  • 1年/2年局部控制率83.3%/78.9%,中位局部复发时间超过36个月。
  • 总照射剂量是总生存和局部控制的唯一显著因素(p=0.015和0.023)。

核心结论

  • 质子束同步放化疗较既往光子同步放化疗数据延长了生存期,且更高剂量照射延长了不可切除局部晚期胰腺癌患者的局部控制和总生存。
  • 作者认为质子束治疗在这些病例中是安全有效的。

研究设计与样本

  • 回顾性分析42例不可切除局部晚期胰腺癌患者(21例男性、21例女性,年龄39-83岁),临床分期IIB/III期为1/41例。
  • 12例接受50 GyE/25次常规剂量方案,30例接受54.0-67.5 GyE/25-33次高剂量方案,同步使用吉西他滨或S-1(替加氟、吉美嘧啶和奥替拉西)。
  • 评估毒性、总生存和局部控制。

主要发现

  • 急性不良事件1级、2级、3级和4级分别见于4例、15例、17例和2例患者,所有3级和4级事件均为血液学毒性。
  • 晚期不良事件1级和2级分别见于3例和2例患者,未观察到3级或以上晚期不良反应。
  • 自同步放化疗开始计算的1年/2年总生存率为77.8%/50.8%,中位生存时间25.6个月。
  • 自同步放化疗开始计算的1年/2年局部控制率为83.3%/78.9%,中位局部复发时间超过36个月。
  • 总照射剂量是总生存和局部控制单因素分析中唯一的显著因素(p=0.015和0.023)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We investigated clinical outcomes of proton beam concurrent chemoradiotherapy (CCRT) for unresectable, locally advanced pancreatic cancer (LAPC) patients. MATERIALS AND METHODS: Records from 42 unresectable LAPC patients (21 male and 21 female, 39-83 years old) with IIB/III clinical staging of 1/41 treated by proton beam CCRT were retrospectively reviewed. Twelve patients received a conventional 50 Gray equivalents (GyE) in 25 fractions protocol and 30 others received a higher dose protocol of 54.0-67.5 GyE in 25-33 fractions. Gemcitabine or S-1 (Tegafur, Gimeracil and Oteracil) was used concurrently. Toxicity, overall survival (OS) and local control (LC) were examined. RESULTS: Acute adverse events of grades 1, 2, 3 and 4 were found in 4, 15, 17 and 2 patients, respectively. All grade 3 and 4 events were hematologic. Late adverse events of grades 1 and 2 were found in 3 and 2 patients, respectively. No late adverse effects of grade 3 or higher were observed. The 1-year/2-year OS rates from the start of CCRT were 77.8/50.8% with median survival time (MST) of 25.6 months. The 1-year/2-year LC rate from CCRT start was 83.3/78.9% with a median time to local recurrence of more than 36 months. Total irradiation dose was the only significant factor in univariate analyses of OS and LC (p = 0.015 and 0.023, respectively). CONCLUSION: Proton beam CCRT lengthened survival periods compared to previous photon CCRT data and higher dose irradiation prolonged LC and OS for unresectable LAPC patients. Proton beam therapy is therefore safe and effective in these cases.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hiroshima Y, Fukumitsu N, Saito T, et al. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. Radiother Oncol. 2019. PMID: 31015127. doi:10.1016/j.radonc.2019.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。